Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Icon has demonstrated strong business growth, with gross business awards increasing by 11% on a sequential basis, supported by significant wins from biotech customers and the expansion of existing partnerships with large pharmaceutical companies. The company has successfully met or exceeded most financial targets related to its PRA acquisition, positioning itself favorably against ongoing funding environment uncertainties, which highlights its robust client and business mix. Additionally, Icon is well-positioned to capitalize on the growth within the contract research organization (CRO) market, indicating enhanced capabilities to accelerate clinical trial research.

Bears say

The financial analysis indicates a negative outlook for Icon's stock, primarily due to an expected decline in EBITDA margins, which are now anticipated to be in the high-19% range compared to previous expectations of approximately 20%. Additionally, the company faces significant downside risks, including potential slowdowns in clinical trial activity due to pharmaceutical reprioritization and uncertainties in biotech funding. These factors, combined with inflationary pressures and a general slowdown in pharmaceutical R&D spending, contribute to concerns over Icon's future financial performance.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.